What are the recommendations for treatment of therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)?

Updated: Dec 05, 2018
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Fixed-dose combination cytarabine/daunorubicin liposomal for newly diagnosed therapy-related (t-AML) or AML with myelodysplasia-related changes (AML-MRC) is as follows:

  • Daunorubicin 29 mg/m² plus cytarabine 65 mg/m² liposome IV on days 1 and 3

  • Initiate the first consolidation cycle 5-8 weeks after the start of the last induction cycle  [22]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!